56074-20-5

Basic information

• Product Name: BOC-IMINODIACETIC ACID
• Synonyms: BOC-IDA;BOC-IDA-OH;BOC-IMINODIACETIC ACID;RARECHEM EM WB 0140;N-BOC-IMINODIACETIC ACID;2,2'-((tert-Butoxycarbonyl)azanediyl)diacetic acid;N-(tert-Butoxycarbonyl)iminodiacetic Acid;N-Boc-iminodiacetic acid >=96.0% (HPLC)
• CAS NO: 56074-20-5
• Molecular Formula: C₉H₁₅NO₆
• Molecular Weight: 233.22
• Product Categories: Glycine Derivatives;Peptide Synthesis;Unnatural Amino Acid Derivatives
• Mol File: 56074-20-5.mol

Chemical Properties

• Melting Point: 117-120 °C
• Boiling Point: 412oC at 760 mmHg
• Flash Point: 203oC
• Appearance: White/Powder
• Density: 1.316g/cm3
• Vapor Pressure: 6.08E-08mmHg at 25°C
• Refractive Index: 1.502
• Storage Temp.: 2-8°C
• Solubility: Methanol
• PKA: 3.45±0.10(Predicted)
• BRN: 4435233
• CAS DataBase Reference: BOC-IMINODIACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: BOC-IMINODIACETIC ACID(56074-20-5)
• EPA Substance Registry System: BOC-IMINODIACETIC ACID(56074-20-5)

Safety Data

• Safety Statements: 22-24/25
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 56074-20-5(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
BOC-IMINODIACETIC ACID is used as a building block for preparing chemical libraries, enabling the development of a diverse range of compounds with potential applications in various fields, such as pharmaceuticals, materials science, and agrochemicals.
Used in Pharmaceutical Industry:
BOC-IMINODIACETIC ACID is used as a novel α4β7 integrin peptide antagonist for the development of new drugs targeting specific biological pathways. This application is particularly relevant in the pharmaceutical industry, where the compound can be utilized to create innovative therapeutic agents for the treatment of various diseases and conditions.
Used in Research and Development:
In the field of research and development, BOC-IMINODIACETIC ACID serves as a valuable tool for the synthesis of new molecules and the exploration of their potential applications. Its unique chemical properties make it an attractive candidate for the development of novel compounds with specific functions and properties, contributing to the advancement of scientific knowledge and the creation of new technologies.

InChI:InChI=1/C9H15NO6/c1-9(2,3)16-8(15)10(4-6(11)12)5-7(13)14/h4-5H2,1-3H3,(H,11,12)(H,13,14)

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 142-73-4 iminodiacetic acid 
• 58632-95-4 2-(tert-Butoxycarbonyloxyimino)-2-phenylacetonitrile 
• 186393-22-6 rac-tert-butyl (3R,4S)-3,4-dihydroxypyrrolidine-1-carboxylate 

Downstream Products

• 175354-29-7 N-((tert-butyloxy)carbonyl)-N'-cyclohexyliminodiacetic acid monoamide 
• 175353-91-0 N-((tert-butyloxy)carbonyl)-N'-(benzyl)iminodiacetic acid monoamide 
• 155788-77-5 ({[Benzyl-(2-{benzyl-[2-(tert-butoxycarbonyl-carboxymethyl-amino)-acetyl]-amino}-ethyl)-carbamoyl]-methyl}-tert-butoxycarbonyl-amino)-acetic acid 
• 211745-69-6 N,N'-bis(N-(2-(4-fluorophenyl)ethyl)carboxamidomethyl)-N,N'-bis(N,N-di(2-methoxyethyl)carboxamidomethyl)-N''-((tert-butoxy)carbonyl)iminodiacetic acid diamide 
• 211745-70-9 N,N'-bis(N-(2-(4-methoxyphenyl)ethyl)carboxamidomethyl)-N,N'-bis(N,N-di(2-methoxyethyl)carboxamidomethyl)-N''-((tert-butoxy)carbonyl)iminodiacetic acid diamide 
• 206867-10-9 N,N'-bis(N-(2-(3,4-dimethoxyphenyl)ethyl)carboxamidomethyl)-N,N'-bis(N-(2-(4-fluorophenyl)ethyl)carboxamidomethyl)-N-((tert-butyloxy)carbonyl)iminodiacetic acid diamide 
• 211745-48-1 bis-[({[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-methyl}-{[2-(4-fluoro-phenyl)-ethylcarbamoyl]-methyl}-carbamoyl)-methyl]-carbamic acid tert-butyl ester 
• 211745-64-1 bis-[({[2-(3,4-dimethoxy-phenyl)-ethylcarbamoyl]-methyl}-{[2-(4-methoxy-phenyl)-ethylcarbamoyl]-methyl}-carbamoyl)-methyl]-carbamic acid tert-butyl ester 
• 211745-49-2 bis-[({[2-(2,5-dimethoxy-phenyl)-ethylcarbamoyl]-methyl}-{[2-(4-methoxy-phenyl)-ethylcarbamoyl]-methyl}-carbamoyl)-methyl]-carbamic acid tert-butyl ester 
• 211745-66-3 bis-({{[2-(4-fluoro-phenyl)-ethylcarbamoyl]-methyl}-[(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-methyl]-carbamoyl}-methyl)-carbamic acid tert-butyl ester 
• 211745-67-4 bis-[([(3-fluoro-5-trifluoromethyl-benzylcarbamoyl)-methyl]-{[2-(4-methoxy-phenyl)-ethylcarbamoyl]-methyl}-carbamoyl)-methyl]-carbamic acid tert-butyl ester 
• 211745-52-7 N,N'-bis(N-(2-(4-methoxyphenyl)ethyl)carboxamidomethyl)-N,N'-bis(N-(3,4,5-trimethoxybenzyl)carboxamidomethyl)-N''-((tert-butoxy)carbonyl)iminodiacetic acid diamide 
• 211745-51-6 bis-({{[2-(4-fluoro-phenyl)-ethylcarbamoyl]-methyl}-[(3,4,5-trimethoxy-benzylcarbamoyl)-methyl]-carbamoyl}-methyl)-carbamic acid tert-butyl ester 
• 211745-63-0 C₆₃H₈₃N₉O₁₆ 

Relevant articles and documents

Trifunctional reagents for substrate-protein conjugation: Application to pyrrolizidine alkaloid analogues

We report the syntheses of two pyrrolizidine alkaloid (PA) analogues (1 and 2) which exploit the novel substrate-protein coupling reagents 4 and 5. Analogues 1 and 2 incorporate the targeted PA substructural unit (i.e., a macrocyclic diester of retronecine), possess a handle for protein conjugation, and potentially maintain the conformational integrity of macrocyclic PAs.

Versatile approach to encoding combinatorial organic syntheses using chemically robust secondary amine tags

Encoded combinatorial organic synthesis has recently emerged as a powerful tool for the discovery of biologically active compounds from complex chemical libraries. This report describes a new encoding methodology that uses chemically robust secondary amines as tags. These amines are incorporated into an N-[(dialkylcarbamoyl)methyl]glycine-coding oligomer through simple chemistry that is compatible with a wide range of polymer-supported transformations useful in combinatorial synthesis. In the decoding process acidic hydrolysis of the tagging polymer regenerates the secondary amines, which after dansylation are resolved and detected at sub-picomole levels by reversed-phase HPLC. The versatility of this strategy is demonstrated here by encoded syntheses of members of several representative heterocyclic compound classes, including β-lactams, 4-thiazolidinones, and pyrrolidines.

Design, synthesis and evaluation of novel bifunctional tetrahydroxamate chelators for PET imaging of89Zr-labeled antibodies

Two compact and symmetrical bifunctional tetrahydroxamate chelators, 1 and 2, were synthesized and evaluated for labeling antibodies with89Zr for imaging with positron emission tomography. Using 2,2′-iminodiacetamide as the backbone, four hydro

CONJUGATES OF A CELL-BINDING MOLECULE WITH CAMPTOTHECIN ANALOGS

Provided are conjugates of camptothecin analogs with a cell-binding molecule of formula (I), wherein R1, R2, R3, R4, R5, X, L, n, m, T and ----- are defined herein. It also provides methods of making the conjugates of camptothecin analogs to a cell-binding agent, as well as methods of using the conjugates in targeted treatment of cancer, infection, and immunological disorders.

Selective Extraction and Complexation Studies for Thorium(IV) with Bis-triamide Extractants: Synthesis, Solvent Extraction, EXAFS, and DFT

Three octyl-extended bis-triamide extractants (L1-L3) were designed and synthesized for the selective solvent extraction of Th(IV) over U(VI) in a kerosene-HNO3system. L1 and L2 exhibited good extraction property and selectivity toward Th(IV) o

Rigid Scaffolds: Synthesis of 2,6-Bridged Piperazines with Functional Groups in all three Bridges

The activity of pharmacologically active compounds can be increased by presenting a drug in a defined conformation, which fits exactly into the binding pocket of its target. Herein, the piperazine scaffold was conformationally restricted by substituted C

Substance related with tophatib and preparation method and application thereof

The invention discloses a substance related with tophatib and a preparation method and application thereof. The substance is named as N,N'-diacetyl{(3R,4R)-4-methyl-3-[methyl(7H-pyrrole[2,3-D]pyrimidine-4-yl)amine]piperidine-1-yl}imine. The impurity is characterized in that the generation level is lower in the condensation reaction process; however, the impurity has the uniform main functional groups with the tophatib, the cleaning effect is limited in the subsequent salting and refining process, and the influence to the qualities of crude drug and finished product of tophatib is larger; by detecting the existence of the impurity, the qualities of the raw material and preparation of the tophatib can be effectively determined.

IONIZABLE CATIONIC LIPID FOR RNA DELIVERY

What is described is a compound of formula I consisting of a compound in which R1 is a branched chain alkyl consisting of 10 to 31 carbons;R2 is a linear alkyl, alkenyl, or alkynyl consisting of 2 to 20 carbons, or a branched chain alkyl consisting of 10 to 31 carbons;L1 and L2 are the same or different, each a linear alkane of 1 to 20 carbons or a linear alkene of 2 to 20 carbons;X1 is S or O;R3 is a linear or branched alkylene consisting of 1 to 6 carbons; andR4 and R5 are the same or different, each a hydrogen or a linear or branched alkyl consisting of 1 to 6 carbons; or a pharmaceutically acceptable salt thereof.

Preparation and application of novel bitriamide organic compounds

The invention belongs to the field of radioactive waste treatment and discloses CHON-element-containing amide organic compounds which can be applied to uranium [U(VI)]/thorium[Th(IV)] separation, plutonium[Pu(IV)]/uranium[U(VI)] separation, lanthanum[Ln(I

Structure-activity relationships of imidazole-derived 2-[ N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme

Insulin degrading enzyme (IDE) is a zinc metalloprotease that degrades small amyloid peptides such as amyloid-a and insulin. So far the dearth of IDE-specific pharmacological inhibitors impacts the understanding of its role in the physiopathology of Alzheimer's disease, amyloid-a clearance, and its validation as a potential therapeutic target. Hit 1 was previously discovered by high-throughput screening. Here we describe the structure-activity study, that required the synthesis of 48 analogues. We found that while the carboxylic acid, the imidazole and the tertiary amine were critical for activity, the methyl ester was successfully optimized to an amide or a 1,2,4-oxadiazole. Along with improving their activity, compounds were optimized for solubility, lipophilicity and stability in plasma and microsomes. The docking or co-crystallization of some compounds at the exosite or the catalytic site of IDE provided the structural basis for IDE inhibition. The pharmacokinetic properties of best compounds 44 and 46 were measured in vivo. As a result, 44 (BDM43079) and its methyl ester precursor 48 (BDM43124) are useful chemical probes for the exploration of IDE's role.